Phase I and pharmacokinetic study of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, by twice daily oral administration between meals in patients with advanced solid tumorsUEDA, Yutaka; SHIMOYAMA, Tatsu; MURAKAMI, Haruyasu et al.Cancer chemotherapy and pharmacology. 2011, Vol 67, Num 5, pp 1101-1109, issn 0344-5704, 9 p.Article

Randomized pharmacokinetic and pharmacodynamic study of docetaxel: Dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisolYAMAMOTO, Noboru; TAMURA, Tomohide; SHIMIZU, Mikiko et al.Journal of clinical oncology. 2005, Vol 23, Num 6, pp 1061-1069, issn 0732-183X, 9 p.Article

Phase I, pharmacokinetic, and biological studies of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, administered after meals with solid tumorsMURAKAMI, Haruyasu; UEDA, Yutaka; SHIMOYAMA, Tatsu et al.Cancer chemotherapy and pharmacology. 2011, Vol 67, Num 5, pp 1119-1128, issn 0344-5704, 10 p.Article

Pharmacokinetics of aprepitant and dexamethasone after administration of chemotherapeutic agents and effects of plasma substance P concentration on chemotherapy-induced nausea and vomiting in Japanese cancer patientsTAKAHASHI, Toshiaki; NAKAMURA, Yukiko; TSUYA, Asuka et al.Cancer chemotherapy and pharmacology. 2011, Vol 68, Num 3, pp 653-659, issn 0344-5704, 7 p.Article

Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumorsYAMAMOTO, Noboru; HORIIKE, Atsushi; FUJISAKA, Yasuhito et al.Cancer chemotherapy and pharmacology. 2008, Vol 61, Num 3, pp 489-496, issn 0344-5704, 8 p.Article

Circulating aminopeptidase N/CD13 is an independent prognostic factor in patients with non-small cell lung cancerMURAKAMI, Haruyasu; YOKOYAMA, Akihito; KONDO, Keiichi et al.Clinical cancer research. 2005, Vol 11, Num 24, pp 8674-8679, issn 1078-0432, 6 p., 1Article

Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumorsMURAKAMI, Haruyasu; DOI, Toshihiko; TAKUBO, Takatoshi et al.Cancer chemotherapy and pharmacology. 2012, Vol 70, Num 3, pp 407-414, issn 0344-5704, 8 p.Article

Expression of 4F2hc (CD98) in pulmonary neuroendocrine tumorsKAIRA, Kyoichi; OHDE, Yasuhisa; KONDO, Haruhiko et al.Oncology reports. 2011, Vol 26, Num 4, pp 931-937, issn 1021-335X, 7 p.Article

Relationship between LAT1 Expression and Response to Platinum-based Chemotherapy in Non-small Cell Lung Cancer Patients with Postoperative RecurrenceKAIRA, Kyoichi; TAKAHASHI, Toshiaki; NAKAJIMA, Takashi et al.Anticancer research. 2011, Vol 31, Num 11, pp 3775-3782, issn 0250-7005, 8 p.Article

Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancerKAIRA, Kyoichi; NAITO, Tateaki; TSUYA, Asuka et al.Lung cancer. 2010, Vol 68, Num 1, pp 99-104, issn 0169-5002, 6 p.Article

Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN™), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumorsYAMAMOTO, Noboru; TAMURA, Tomohide; YAMAZAKI, Kentaro et al.Cancer chemotherapy and pharmacology. 2009, Vol 64, Num 6, pp 1165-1172, issn 0344-5704, 8 p.Article

Increases of amphiregulin and transforming growth factor-α in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancersISHIKAWA, Nobuhisa; DAIGO, Yataro; TSUCHIYA, Eiju et al.Cancer research (Baltimore). 2005, Vol 65, Num 20, pp 9176-9184, issn 0008-5472, 9 p.Article

Molecular profiling of small cell lung cancer in a Japanese cohortWAKUDA, Kazushige; KENMOTSU, Hirotsugu; MORI, Keita et al.Lung cancer. 2014, Vol 84, Num 2, pp 139-144, issn 0169-5002, 6 p.Article

Efficacy and Safety of Platinum Combination Chemotherapy Re-Challenge for Relapsed Patients with Non-Small-Cell Lung Cancer after Postoperative Adjuvant Chemotherapy of Cisplatin plus VinorelbineIMAI, Hisao; SHUKUYA, Takehito; MURAKAMI, Haruyasu et al.Chemotherapy (Basel). 2013, Vol 59, Num 4, pp 307-313, issn 0009-3157, 7 p.Article

Biologic correlates of ¹⁸F-FDG uptake on PET in pulmonary pleomorphic carcinomaKAIRA, Kyoichi; ENDO, Masahiro; NAITO, Tateaki et al.Lung cancer. 2011, Vol 71, Num 2, pp 144-150, issn 0169-5002, 7 p.Article

Prognostic Significance of Thymidylate Synthase Expression in the Adjuvant Chemotherapy after Resection for Pulmonary Metastases from Colorectal CancerKAIRA, Kyoichi; OKUMURA, Takehiro; OHDE, Yasuhisa et al.Anticancer research. 2011, Vol 31, Num 9, pp 2763-2771, issn 0250-7005, 9 p.Article

Expression of thymidylate synthase, orotate phosphoribosyltransferase and dihydropyrimidine dehydrogenase in thymic epithelial tumorsKAIRA, Kyoichi; SERIZAWA, Masakuni; TSUYA, Asuka et al.Lung cancer. 2011, Vol 74, Num 3, pp 419-425, issn 0169-5002, 7 p.Article

Efficacy of chemotherapy with carboplatin and paclitaxel for unresectable thymic carcinomaIGAWA, Satoshi; MURAKAMI, Haruyasu; ENDO, Masahiro et al.Lung cancer. 2010, Vol 67, Num 2, pp 194-197, issn 0169-5002, 4 p.Article

Efficacy of bevacizumab-containing chemotherapy for non-squamous non-small cell lung cancer with bone metastasesTOKITO, Takaaki; SHUKUYA, Takehito; YAMAMOTO, Nobuyuki et al.Cancer chemotherapy and pharmacology. 2013, Vol 71, Num 6, pp 1493-1498, issn 0344-5704, 6 p.Article

Prognostic Factors and Clinical Outcome of Patients with Lung Adenocarcinoma with Carcinomatous MeningitisNAKAMURA, Yukiko; TAKAHASHI, Toshiaki; ENDO, Masahiro et al.Anticancer research. 2012, Vol 32, Num 5, pp 1811-1816, issn 0250-7005, 6 p., aArticle

Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: A pooled analysis of published reportsSHUKUYA, Takehito; TAKAHASHI, Toshiaki; ENDO, Masahiro et al.Cancer science. 2011, Vol 102, Num 5, pp 1032-1037, issn 1347-9032, 6 p.Article

MUC1 expression in thymic epithelial tumors: MUC1 may be useful marker as differential diagnosis between type B3 thymoma and thymic carcinomaKAIRA, Kyoichi; MURAKAMI, Haruyasu; SERIZAWA, Masakuni et al.Virchows Archiv. 2011, Vol 458, Num 5, pp 615-620, issn 0945-6317, 6 p.Article

L-Type Amino Acid Transporter 1 (LAT1) Expression in Malignant Pleural MesotheliomaKAIRA, Kyoichi; ORIUCHI, Noboru; KANAI, Yoshikatsu et al.Anticancer research. 2011, Vol 31, Num 12, pp 4075-4082, issn 0250-7005, 8 p.Article

Gefitinib Plus Paclitaxel after Failure of Gefitinib in Non-small Cell Lung Cancer Initially Responding to GefitinibSHUKUYA, Takehito; TAKAHASHI, Toshiaki; ENDO, Masahiro et al.Anticancer research. 2009, Vol 29, Num 7, pp 2747-2751, issn 0250-7005, 5 p.Article

Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumorsYAMADA, Yasuhide; TAMURA, Tomohide; MCGOVREN, J. Patrick et al.Cancer chemotherapy and pharmacology. 2006, Vol 58, Num 2, pp 173-182, issn 0344-5704, 10 p.Article